Human aging and the GH-IGF-I axis

Journal of Pediatric Endocrinology and Metabolism

Volumn 9, Issue SUPPL., 1996, Pages 271-278

  Ghigo, Ezio ^a,b   Arvat, Emanuela ^a   Gianotti, Laura ^a   Ramunni, Josefina ^a   DiVito, Lidia ^a   Maccagno, Barbara ^a   Grottoli, Silvia ^a   Camanni, Franco ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

GH; GHRH; GHRPS; IGF I; Neurotransmitters; Somatostatin

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING PEPTIDE; HUMAN GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOSTATIN; UNCLASSIFIED DRUG;

AGE; AGING; CIRCADIAN RHYTHM; CONFERENCE PAPER; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE;

AGING; ANIMALS; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 0029758671     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Casanueva FF. Physiology of growth hormone secretion and action. In: Melmed S, ed. Endocrinology and Metabolism Clinics of North America. Philadelphia: Saunders Company, 1992; 483-517.
2. Dieguez C, Page MD, Scanlon MF. Growth neuroregulation and its alterations in disease states. Clin Endocrinol 1988; 28: 109-143.
3. Corpas E, Harman SM, Blackman S. Human growth hormone and human aging. Endocr Rev 1993; 14: 20-39.
4. Ghigo E, Arvat E, Goffi S, Bellone J, Nicolosi M, Procopio M, et al. Neural control of growth hormone secretion in aged humans. In: Müller EE, Cocchi D, Locatelli V, eds. Growth Hormone and Somatomedins During Lifespan. Berlin: Springer Verlag, 1993: 275-287.
5. Zadik Z, Chalew SA, McCarter RJ, Meistas M, Kowarski AA. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 1985; 60: 513-516.
6. Vermeulen A. Nyctohemeral growth hormone profiles in young and aged men: correlation with somatomedin-C levels. J Clin Endocrinol Metab 1987; 64: 884-888.
7. Van Coevorden A, Mockel J, Laurent E. Neuroendocrine rhythms and sleep in aging men. Am J Physiol 1991; 260: 251-261.
8. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of GH secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991; 73: 1081-1088.
9. Rudman D, Feller AG, Nagraj HS. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6.
10. Corpas E, Harman M, Pineyro MA, Roberson R, Blakman R. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992; 75: 530-535.
11. Clemrnons DR, Van Wyk J. Factors controlling blood concentration of somatomedin C. J Clin Endocrinol Metab 1984; 13: 113-120.
12. Pohelman ET, Copeland KC. Influence of physical activity on insulin-like growth factor-I levels in healthy younger and older men. J Clin Endocrinol Metab 1990; 71: 1468-1473.
13. Rudman D, Kutner MH, Rogers M, Lubin MF, Fleming GA, Bain RP. Impaired growth hormone secretion in the adult population. J Clin Invest 1981; 67: 1361-1369.
14. Ceda GP, Valenti G, Butturini U, Hoffman AR. Diminished pituitary responsiveness to growth hormone-releasing factor in aging male rats. Endocrinology 1986; 118: 2109-2114.
15. Morimoto N, Kawakami F, Makino S, Chihara K, Hasegawa M, Ibata Y. Age-related changes in growth hormone releasing factor and somatostatin in the rat hypothalamus. Neuroendocrinology 1988; 47: 459-464.
16. DeGennaro V, Zoli M, Cocchi D. Reduced growth hormone releasing factor (GHRH)-like immunoreactivity and GHRH gene expression in hypothalamus of aged rats. Peptides 1989; 10: 705-708.
17. Ghigo E, Arvat E, Valente F, Nicolosi M, Boffano GM, Procopio M, et al. Arginine reinstates the growth hormone responsiveness to intermittent administration of growth hormone-releasing hormone in man. Neuroendocrinology 1991; 54: 291-294.
18. Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, et al. Effect of 15-day treatment with growth-hormone-releasing hormone alone or combined with different doses of arginine on the reduced somatotrope responsiveness to the neurohormone in normal aging. Eur J Endocrinol 1995; 132: 32-36.
19. Sonntag WE, Forman LJ, Miki N, Steger RW, Ramos T, Arimura A, et al. Effects of CNS active drugs and somatostatin antiserum on growth hormone release in young and old male rats. Neuroendocrinology 1981; 33: 73-76.
20. Ge F, Tsagarakis S, Rees LH, Besser CM, Grossman A. Relationship between growth hormone-releasing hormone and somatostatin in the rat: effects of age and sex on content and in-vitro release from hypothalamic explants. J Endocrinol 1989; 123: 53-58.
21. Locatelli V, Cella SG, Cermenati P, Panzeri G, Sellan R, Müller EE. Defective growth hormone (GH) secretion in aging mammals: contribution of central and peripheral inhibitory influences and of GH-releasing hormone. In: Valenti G, ed. Psychoneuroendocrinology of Aging: Basic and Clinical Aspects. Padova: Fidia Research Series; Liviana Press, 1989; 61-67.
22. Ghigo E, Goffi S, Arvat E, Nicolosi M, Procopio M, Bellone J, et al. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging. Acta Endocrinol (Copenh) 1990; 123: 169-174.
23. Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, et al. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. J Clin Endocrinol Metab 1990; 71: 1481-1485.
24. Giustina A, Bussi AR, Conti C, Doga M, Legati F, Macca C, et al. Comparative effect of galanin and pyridostigmine on the growth hormone response to growth hormone-releasing hormone in normal aged subjects Horm Res 1992; 37: 165-170.
25. Giusti M, Giovale M, Grossman A, Marini G, Drago T, Uggias B, et al. Opioid analogue metenkephalin does not potentiate GH release after GHRH in elderly men. J Endocrinol Invest 1992; 15 (Suppl 4): 119.
26. Wehrenberg WB, Ling N. The absence of an agerelated change in the pituitary response to growth-hormone-releasing factor in rats. Neuroendocrinology 1983; 37: 463-466.
27. Ghigo E, Goffi S, Arvat E, Imperiale E, Boffano GM, Valetto MR, et al. A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging. J Endocrinol Invest 1992; 15: 665-668.
28. Ceda GP, Ceresini G, Denti L, Marzani G, Piovani E, Banchini A, et al. Alpha-glycerylphosphorylcholine administration increases the GH responses to GHRH of young and elderly subjects. Horm Metab Res 1992; 24: 119-121.
29. Panzeri G, Torsello A, Cella SG, Müller EE, Locatelli V. Age-related modulatory activity by a cholinergic agonist on the GH response to GHRH in the rat. PSEMB 1990; 193: 301.
30. White P, Hiley CR, Goodhardt MJ. Neocortical cholinergic neurons in elderly people. Lancet 1977; 1: 668-671.
31. Barthus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory disfunction. Science 1982; 217: 408-417.
32. Gibson GE, Peterson C, Jender DJ. Brain acetylcholine synthesis declines with senescence. Science 1981; 213: 675-678.
33. Richardson SB, Hollander GS, D'Eletto SD, Greenleaf PW, Than C. Acetylcholine inhibits the release of somatostatin from rat hypothalamus in vitro. Endocrinology 1980; 107: 1837-1842.
34. Rossor MM. Dementia. Lancet 1982; II: 1200-1204.
35. Ghigo E, Nicolosi M, Arvat E, Marcone A, Danelon F, Mucci M, et al. Growth hormone secretion in Alzheimer's disease: studies with growth hormone-releasing hormone alone and combined with pyridostigmine or arginine. Dementia 1993; 4; 315-320.
36. Wisnieski KE, Howe J, Williams DG, Wisnieski HM. Precocious aging and dementia in patients with Down's syndrome. Biol Psychiat 1978; 13: 619-627.
37. Gianotti L, Arvat E, Ragusa L, Cappa M, Aimaretti GL, Ramunni J, et al. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down's syndrome. VI Congress of the Italian Society of Neuroscience 1995; 99: 93 (Abst).
38. Raskind MA, Peskind ER, Veith RC, Beard JC, Gumbrecht G, Halter B. Increased plasma and cerebrospinal fluid norepinephrine in older men: differential suppression by clonidine. J Clin Endocrinol Metab 1988; 66: 438-440.
39. Cella SG, Arce VM, Pieretti F, Locatelli V, Settembrini BP, Müller EE. Combined administration of growth hormone-releasing hormone and clonidine restores defective growth hormone secretion in old dogs. Neuroendocrinology 1993; 57: 432-438.
40. Gil-Ad I, Gurewitz R, Marcovici O, Rosenfeld J, Laron Z Effects of aging on human plasma growth hormone response to clonidine. Mech Ageing Dev 1984; 27: 97-100.
41. Bowers CY. GH releasing peptides - Structure and kinetics. J Pediatr Endocrinol 1993; 6: 21-31.
42. Penalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine or hypoglycemia on GHRP-6-induced GH secretion in man. J Clin Endocrinol Metab 1993; 76: 168-171.
43. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, et al. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. J Clin Endocrinol Metab 1994; 78: 693-698.
44. Momany FA, Bowers CY, Reynolds GA, Hong A, Newlander K. Conformational energy studies and in vitro and in vivo activity data on active GH releasing peptides. Endocrinology 1984; 114: 1531-1536.
45. Badger TM, Millard WY, McCormik GH, Bowers CY, Martin JB. The effects of growth hormone (GH)-releasing peptides on GH secretion in perifused pituitary cells of adult male rats. Endocrinology 1984; 115: 1432-1438.
46. Codd EE, Shu AYL, Walker RF. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989; 28: 1139-1144.
47. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the action of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991; 128: 2027-2035
48. Goth MI, Lyons CE, Canny BY, Thorner MO. Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 1992; 130: 939-944.
49. Bellone J, Aimaretti G, Bartolotta E, Benso L, Imbimbo BP, Lenaerts V, et al. Growth hormone-releasing activity of Hexarelin, a new synthetic hexa-peptide, before and during puberty. J Clin Endocrinol Metab 1995; 80: 1090-1094.
50. Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi M, Boffano GM, et al. Arginine enhances the growth hormone(GH)-releasing activity of a synthetic hexa-peptide (GHRP-6) in elderly but not in young subjects after oral administration. J Endocrinol Invest 1994; 17: 157-162.
51. Ghigo E, Arvat E, Rizzi G, Goffi S, Mucci M, Boghen MF, et al. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. Eur J Endocrinol 1994; 131: 1-4.
52. Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, et al. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of Hexarelin in elderly subjects. J Clin Endocrinol Metab 1994; 79: 1440-1443.
53. Bowers CY, Veeraragavan K, Sethumadhavan K. Atypical growth hormone releasing peptides. In: Bereu BB, Walker RF, eds. Growth Hormone II, Basic and Clinical Aspects. New York: Springer-Verlag, 1993; 203-222.
54. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990; 70: 975-982.
55. Penalva A, Pombo M, Carballo Barreiro J, Casanueva FF, Dieguez C. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clin Endocrinol 1993; 38: 87-91.
56. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamo pituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalatnic level. J Clin Endocrinol Metab 1995; 80: 942-947.
57. Arvat E, Gianotti L, Di Vito L, Intbimbo BP, Lenaerts V, Deghenghi R, et al. Modulation of growth hormone-releasing activity of Hexarelin in man. Neuroendocrinology 1995; 61: 51-56.
58. Maccario M, Arvat E, Procopio M, Gianotti L, Grottoli S, Imbimbo BP, et al. Metabolic modulation of the growth hormone-releasing activity of Hexarelin in man. Metabolism 1995; 44: 134-138.
59. Dickson S, Leng G, Dyball REJ, Smith RG. Central actions of peptide and non-peptide growth hormone secretagogues in the rat. Neuroendocrinology 1995; 61: 36-43.
60. Guillame V, Magnan E, Cataldi M, Dutour A, Sauze N, Renard M, et al. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexa-peptide in sheep. J Clin Endocrinol Metab 1994; 135: 1073-1076.
61. Clark RG, Carlsson LMS, Trojnar J, Robinson ICAF. The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anaesthetized rats. J Neuroendocrinol 1989; 1: 249-255.
62. 2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′,5′-monophosphate accumulation in rat primary cell culture. Endocrinology 1989; 124: 2791-2798.
63. Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, et al. Aging and GH-releasing peptides. In: Bereu B, Walker R, eds. GH Secretagogues. USA: Serono Symposia, 1995; in press.
64. Craig BWR, Brown JE. Effects of progressive resistance training on growth hormone testosterone levels in young and elderly subjects. Mech Ageing Develop 1989; 49: 159-169.
65. Pyka G, Wiswell RA, Marcus R. Age-dependent effect of resistance exercise on growth hormone secretion in people. J Clin Endocrinol Metab 1992; 75: 404-407.
66. Thompson JL, Butterfield CE, Marcus R, Hintz RL, Van Loan M, Ghiron L, Hoffman AR. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 1995; 80: 1845-1852.
67. Smith RG, Cheng K, Schoen WR, Pong SS, Hicley G, Jacks T, et al. A non-peptidyl growth hormone secretagogue. Science 1995; 260: 1640-1643.
68. Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, et al. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone-releasing hormone in elderly subjects. J Endocrinol Invest 1994; 17: 113-122.
69. Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, et al. Short term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the GH responsiveness in human aging. Eur J Endocrinol 1996; in press.
70. th Annual Meeting of the Endocrine Society 1995; 347 (Abst).
71. th Annual Meeting of the Endocrine Society 1995; 508 (Abst).
72. Lieberman SA, Mitchell AM, Marcus R, Hintz R, Huffman AR. The insulin-like growth factor I generation test: resistance to growth hormone with aging and estrogen replacement therapy. Horm Metab Res 1994; 26: 229-233.
73. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor 1 by use of both agents simultaneously. J Clin Invest 1993; 91: 391-393.
74. Isaksson OGP, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev 1987; 8: 426-438.